Thank you for writing to us. One of our executive will reach back to you through your submitted medium. In case there’s an urgency, feel free to connect over WhatsApp for faster response.
Prefer calling? Dial +918806001214 (International callers) or +918806001214 (Indian callers).
COMPOSITION:
Each film-coated tablet contains: Selinexor ……………………… 20mg
INDICATION:
LuciSelin is a nuclear export inhibitor indicated:
· In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
· In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
· For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
DOSAGE AND USE:
1 Multiple Myeloma in Combination with Bortezomib and Dexamethasone (Svd):
The recommended dosage of LuciSelin is 100 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with:
· Bortezomib 1.3 mg/m administered subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off.
· Dexamethasone 20 mg taken orally twice weekly on Days 1 and 2 of each week.
1.2 Multiple Myeloma in Combination with Dexamethasone (Sd):
The recommended dosage of LuciSelin is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20mg taken orally with each dose of LuciSelin on Days 1 and 3 of each week.
2 DLBCL: Recommended dosage of LuciSelin is 60 mg taken orally on Days 1 and 3 of each week.
Tablet should be swallowed whole & not chewed or crushed.
STORAGE:
Store at or below 30°C, in a dry place.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each film-coated tablet contains Quizartinib dihydrochloride 20 mg equivalent to Quizartinib…………………………………17.7mg.
INDICATION:
LuciQuiza is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
DOSAGE AND USE:
• Take LuciQuiza tablets orally once daily with or without food at approximately the same time each day.
• See Full Prescribing Information for recommended LuciQuiza dosage regimen and dosage modifications.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each film-coated tablet contains Belumosudil mesylate 242.5mg equivalent to Belumosudil ………………………. 200mg.
INDICATION:
LuciBelu is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
DOSAGE AND USE:
Recommended Dosage: 200 mg taken orally once daily with food.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each film-coated tablet contains Tepotinib hydrochloride hydrate 250mg equivalent to Tepotinib…………………………….225mg.
INDICATION:
LuciTepo is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal epithelial transition (MET) exon 14 skipping alterations.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE AND USE:
• Select patients for treatment with LuciTepo on the presence of METex14 skipping.
• Recommended dosage: 450mg orally once daily with food until disease progression or unacceptable toxicity.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
